Sponsor

Immunic AG

Clinical research sponsor

Published trials5
Recruiting shown0
Roles1
SourceClinicalTrials.gov

Clinical trials

5 shown
Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple SclerosisNCT05201638 · lead sponsor · 2022-01-12
ACTIVE_NOT_RECRUITING
IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate CancerNCT05124795 · lead sponsor · 2021-12-09
TERMINATED
Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple SclerosisNCT05134441 · lead sponsor · 2021-11-18
ACTIVE_NOT_RECRUITING
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple SclerosisNCT05054140 · lead sponsor · 2021-09-30
UNKNOWN
MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)NCT03846219 · lead sponsor · 2019-01-28
ACTIVE_NOT_RECRUITING

Sponsor roles

lead sponsor5

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.